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In Niemann-Pick disease type C (NPC), a genetic heterogeneity with two complementation groups—NPC1, com-
prising 95% of the families, and NPC2—has been demonstrated. Mutations in the NPC1 gene have now been
well characterized. HE1 was recently identified as the gene underlying the very rare NPC2. Here we report the first
comprehensive study of eight unrelated families with NPC2, originating from France, Algeria, Italy, Germany, the
Czech Republic, and Turkey. These cases represent essentially all patients with NPC2 who have been reported in
the literature, as well as those known to us. All 16 mutant alleles were identified, but only five different mutations,
all with a severe impact on the protein, were found; these five mutations were as follows: two nonsense mutations
(E20X and E118X), a 1-bp deletion (27delG), a splice mutation (IVS2+5GrA), and a missense mutation (S67P)
resulting in reduced amounts of abnormal HE1 protein. E20X, with an overall allele frequency of 56%, was
established as the common mutant allele. Prenatal diagnosis was achieved by mutation analysis of an uncultured
chorionic-villus sample. All mutations except 27delG were observed in a homozygous state, allowing genotype/
phenotype correlations. In seven families (with E20X, E118X, S67P, and E20X/27delG mutations), patients suffered
a severe and rapid disease course, with age at death being 6 mo–4 years. A remarkable feature was the pronounced
lung involvement, leading, in six patients, to early death caused by respiratory failure. Two patients also developed
a severe neurological disease with onset during infancy. Conversely, the splice mutation corresponded to a very
different clinical presentation, with juvenile onset of neurological symptoms and prolonged survival. This mutation
generated multiple transcripts, including a minute proportion of normally spliced RNA, which may explain the
milder phenotype.
Introduction
Niemann-Pick disease type C (NPC [MIM 257220 and
MIM 601015]) is an autosomal recessive lysosomal lipid-
storage disorder with a protean clinical presentation (Pat-
terson et al. 2001). The disease is most commonly char-
acterized by hepatosplenomegaly and a severe progressive
neurological dysfunction with varying age at onset and
varying later course. The cellular hallmark of NPC is a
late-endosomal/lysosomal accumulation of endocytosed
unesterified cholesterol. In tissues, there is a complex pat-
tern of accumulating lipids that differs between nonneural
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organs and brain, with no overall increase of sphingo-
myelin and cholesterol in the latter (Vanier and Suzuki
1996; Blanchette-Mackie 2000; Patterson et al. 2001).
A genetic heterogeneity was established in NPC by
somatic-cell hybridization and linkage analysis, defining
two different genetic complementation groups, NPC1
and NPC2 (Steinberg et al. 1994; Vanier et al. 1996).
Because identical cellular and biochemical phenotypes
were observed in patients belonging to the two genetic
complementation groups (Vanier et al. 1996; Christo-
manou et al. 2000), it has been concluded that both
gene products may function either in tandem or se-
quentially (Vanier et al. 1996). TheNPC1 gene (mapped
to 18q11), mutated in 95% of families with NPC, was
isolated by positional cloning and has been fully char-
acterized (Carstea et al. 1997; Morris et al. 1999). The
4.7-kb NPC1 cDNA sequence encodes a 1,278-amino-
acid protein, shown to contain 13 transmembrane do-
mains, three large luminal loops, four small luminal
loops, six small cytoplasmic loops, and one cytoplasmic
tail (Davies and Ioannou 2000). It also contains a sterol-
Table 1
Clinical and Biochemical Survey of Families with NPC2
Patient ID (Ethnicity) Age at Death Clinical Summary Consanguinity?
LDL-Induced
Cholesteryl-Ester
Formationa Reference(s)
Case 1 (French) 6 mo Female; hydramnios, cesarean section at 32 wk gestation,
respiratory distress from birth, moderate neonatal cholestatic
icterus at age 4–30 d, hepatosplenomegaly, respiratory
failure (two affected siblings were diagnosed prenatally, and
the pregnancies were terminated)
No !10
Case 2 (French) 6 mo Female; fetal ascites (that recessed) at 23 wk gestation,
hepatosplenomegaly at birth, cholestatic icterus at age 1 mo,
severe respiratory insufficiency from age 3 mo, respiratory
failure
No 50 Pin et al. (1990), Vanier et al.
(1996) (case 16)
Case 3 (Italian) 6 mo Female; neonatal cholestatic icterus, hepatosplenomegaly,
respiratory failure (three further affected siblings were
diagnosed prenatally, and the pregnancies were terminated)
No 75 Steinberg et al. (1994), Vanier
et al. (1996) (case 19), Nau-
reckiene et al. (2000)
Case 4 (German) 7 mo Female; neonatal period uneventful, severe interstitial
pneumonia/hepatosplenomegaly/respiratory insufficiency/
failure at age 3 mo (a brother with “neonatal hepatitis” and
severe lung involvement had died at age 6 wk)
Yes 320 Schofer et al. (1998), Vanier
et al. (1996) (case 28)
Case 5 (Algerian) 19 mo Male; neonatal cholestatic icterus until age 4 mo, then
pulmonary involvement; severe motor development delay
from age 7–9 mo (able to sit only at age 15 mo, no further
progress); growth retardation, increasing pulmonary fibrosis,
oxygen dependency, respiratory failure
Yes 10 Vanier et al. (1996) (case 2)
Case 6 (Czech) 4 years Female; failure to thrive (with poor feeding), hepatospleno-
megaly and mild delay of motor milestones at age 1 year,
severe lung involvement, oxygen dependent from age 20 mo,
quadruspasticity
No 45 Christomanou et al. (2000),
Elleder et al. (2001)
Case 7 (Turkish) Alive (at 20 mo) Female; no neonatal cholestatic icterus; respiratory distress and
pulmonary infiltration at age 11 mo, (hepato-)splenomegaly; new
acute respiratory problems at age 13 mo, at which psychomotor
development was normal; hypotonia and gait problems from
age 18 mo (an elder brother had splenomegaly and died, of
respiratory distress, at age 6 mo in Turkey)
Yes 10
Case 8 (Algerian) Alive (at 21 years) Female; splenomegaly at age 6.5 years, school problems,
epileptic fits at age 11 years, mental retardation, slow
progression, still able to walk normally at age 21 years (an
affected sister with quite similar course was still alive at age
27 years)
Yes 380 Vanier et al. (1996) (case 27)
a After 4.5 h, expressed as pmol/mg cell protein, studied as described by Vanier et al. (1991) (normal values ).2,950 1,200
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Table 2
Oligonucleotide Sequences
Oligonucleotide
Sequencea
(5′r3′)
NPC2-ex1s gctgtggttactggtgacagg
NPC2-ex1as tccaaggctcagcctggccg
NPC2-ex2s ctaaatgggagagcagagcac
NPC2-ex2as ccctccattcccatgcttattc
NPC2-ex3s atgcttgcactgtgctagtac
NPC2-ex3as tgatgcctaacaccgcaccta
NPC2-ex4s ggagttaggaagtttgctactg
NPC2-ex4as tggcactgatttagtttcagtc
NPC2-ex5s gccctgacagtggaggaaag
NPC2-ex5as ggcctgccttccatggttct
NPC2-ADNcs(3)b 21CTTGGAACTTCGTTATCCGCG1
NPC2-ADNcas(2)b 535TGTTGAAGCAGCAGAGCTGG516
a Exonic sequences are given in uppercase, and intronic sequences
are given in lowercase.
b Counted from the adenosine residue of the initiation codon.
sensing domain with the same orientation as that of
HMG-CoA reductase and SCAP (sterol regulatory el-
ement binding protein [SREBP] cleavage activation pro-
tein) (Davies and Ioannou 2000). Approximately 100
different NPC1 mutations have already been identified
in patients with NPC1 (Carstea et al. 1997; Greer et al.
1998, 1999; Yamamoto et al. 1999, 2000; Millat et al.
2001; Ribeiro et al. 2001; Sun et al. 2001); they have
been shown to affect all domains of the protein—with
some predilection, however, for a conserved cysteine-
rich luminal loop (Greer et al. 1999; Millat et al. 2001).
Only three of these mutations—I1061T, G992W, and
P1007A—appear to occur quite frequently (Greer et al.
1998; Millat et al. 1999, 2001). The NPC1 protein re-
sides in late endosomes and interacts transiently with
lysosomes and with the trans-Golgi network (Higgins
et al. 1999; Neufeld et al. 1999). The exact cellular
function of NPC1 and the role that it has in intracellular
trafficking of lipids remain unclear (Liscum and Munn
1999; Blanchette-Mackie 2000; Cruz et al. 2000; Davies
et al. 2000; Ory 2000). A number of studies suggest
that NPC1 has a key role in the modulation of vesicular
trafficking of cholesterol and of glycolipids (Neufeld et
al. 1999; Blanchette-Mackie 2000; Zhang et al. 2001),
but recent data suggest that NPC1 is a permease acting
as a transmembrane efflux pump (Davies et al. 2000).
To date, only eight families belonging to the minor,
NPC2 complementation group (MIM 601015), esti-
mated to account for 5% of families with NPC, have
been documented (Steinberg et al. 1994, 1996; Vanier
et al. 1996; Christomanou et al. 2000; Naureckiene et
al. 2000; Elleder et al. 2001). Recently, by a proteomic
approach, the HE1 gene (mapped to 14q24) was iden-
tified as the disease-causing gene in patients with NPC2
(Naureckiene et al. 2000). For practical reasons and by
analogy with NPC1, we propose henceforth to use the
name “HE1/NPC2.” HE1/NPC2 is ∼13.5 kb long and
is composed of five exons of size 78–342 bp (Naureck-
iene et al. 2000). Analysis of the 822-bp cDNA sequence
showed an open reading frame of 453 bp, followed by
a 3′ UTR of 327 bp comprising most of exon 5 (Kirch-
hoff et al. 1996). Translation of HE1/NCP2 leads to a
mature protein of 132 amino acid residues, with a the-
oretical molecular mass of 14.5 kD.
The HE1/NPC2 glycoprotein (GenBank) was first
characterized as a major secretory protein in the human
epididymis (Kirchhoff et al. 1996) and was also shown
to bind cholesterol (Baker et al. 1993; Okamura et al.
1999). It is now known to be a small, soluble, ubiq-
uitously expressed lysosomal protein, the functional al-
teration of which leads to an NPC phenotype (Nau-
reckiene et al. 2000). In the original study establishing
HE1 as the gene underlying NPC2, severe mutations
leading to absence of HE1 protein were reported in two
patients (Naureckiene et al. 2000). One patient carried
a homozygous E20X mutant allele, and the other pa-
tient was a compound heterozygote for the E20X mu-
tation and for a single-nucleotide deletion (311delA) in
exon 2. In the present report, the molecular defect has
been characterized in a further seven unrelated families
with NPC2 and has been applied to rapid first-trimester
prenatal diagnosis of the condition. Furthermore, the
clinical and biochemical phenotypes in the eight families
can now be better understood in terms of the underlying
genetic mutations.
Subjects, Material, and Methods
Subjects and Biological Material
Fibroblast strains from eight unrelated patients with
NPC2 (six previously documented cases and two from
newly diagnosed families) were used in the study. The
diagnosis of NPC disease had been assessed by filipin
staining and by measurement of LDL-induced choles-
teryl-ester formation, as described elsewhere (Vanier et
al. 1991) (table 1). Complementation analysis by so-
matic-cell hybridization and by filipin staining had pre-
viously been documented in a majority of the cases
(Steinberg et al. 1994; Vanier et al. 1996; Schofer et al.
1998) and, in the remaining three families (cases 1, 6,
and 7), was performed by the simplified procedure de-
scribed by Schofer et al. (1998). Genomic DNAwas also
available from parents of cases 1, 3, and 6–8 and from
four affected fetuses who would have been siblings of
cases 1 and 3. The main clinical and biochemical features
of the patients with NPC2 are summarized in table 1.
Genomic DNA Extraction
Genomic DNA was extracted from cultured skin fi-
broblasts, peripheral blood leukocytes, and uncultured
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Table 3
Spectrum of Mutations Identified in Patients with NPC2
Patient (Cell Line) Genotype
Nucleotide
Change(s)a Location(s) Predicted Protein Alteration(s)
Case 1 (20082) E20X/E20X G58T Exon 1 Stop at codon 20
Case 2 (88082) E20X/27delG G58T/27delG Exon 1/exon 1 Stop at codon 20/frameshift from codon 9;
premature termination codon  24
amino acids
Case 3 (88057/NIH99.04b) E20X/E20X G58T Exon 1 Stop at codon 20
Case 4 (93104) E118X/E118X G352T Exon 3 Stop at codon 118
Case 5 (89095) E20X/E20X G58T Exon 1 Stop at codon 20
Case 6 (96059) E20X/E20X G58T Exon 1 Stop at codon 20
Case 7 (21033) S67P/S67P T199C Exon 3 S67P
Case 8 (82017/NIH94.85b) IVS25GrA/IVS25GrA … Intron 2 Multiple mRNAs (see text and fig. 1)
a Counted from the adenosine residue of the initiation codon.
b New code, assigned after the strains were transferred to the National Institutes of Health (NIH) within the frame of a collaboration
between either A.H.F. or M.T.V. and Dr. P. G. Pentchev.
chorionic-villus samples, by standard procedures (Jean-
pierre 1987; Miller et al. 1998)
Sequencing
After amplification, PCR products were purified and
directly sequenced in both directions by the Thermo-
sequenase cycle sequencing kit and were primer labeled
with g[33P]-ATP at 3,000 Ci/mmol (Amersham Phar-
macia Biotech).
RNA Isolation and cDNA Synthesis
Total RNA was isolated from fibroblast monolayers
by Trizol reagent (Life Technologies), and reverse tran-
scription was performed with oligo-dT primer, by the
First Strand cDNA synthesis kit (Amersham Pharmacia
Biotech) according to the manufacturers’ instructions.
Subcloning
cDNA from case 8 was amplified by primers NPC2-
ADNcs(3) and NPC2-ADNcas(2) (table 2). PCR prod-
ucts were purified and subcloned into pGEM-T vector
(Promega). After transformation, 32 isolated subclones
were sequenced in both directions.
Mutation Detection of the E20X Nonsense Mutation in
Genomic DNA
Exon 1 of HE1/NPC2 was PCR amplified by the
primers NPC2-ex1s and NPC2-ex1as (table 2). The 40
PCR cycles each included steps of 1 min at 92C, 1
min at 62C, and 1 min at 72C. Because the mutation
created a StuI restriction site, the 325-bp PCR product
was digested for 2 h at 37C by StuI and was analyzed
on 3% Nusieve-GTG gels (BioWhitaker Molecular
Applications).
Western Blot Studies
For western blot studies, fibroblast lysates were pre-
pared as described by Naureckiene et al. (2000), and
soluble protein (10 mg protein/lane) was separated on
12% SDS-acrylamide gels. The blot was probed with
rabbit antibodies to HE1/NPC2 (Naureckiene et al.
2000), followed by chemiluminescence by the ECL de-
tection kit (Amersham Pharmacia Biotech).
Results
Spectrum of HE1/NPC2 mutations
Sequencing of all five exons ofHE1/NPC2 and of their
boundaries was performed on genomic DNA isolated
from all patients except proband 3, who was included
in the initial, “HE1” study (Naureckiene et al. 2000;
case NPC2-99-04). All 14 new mutant alleles were char-
acterized. As shown in table 3, only five different mu-
tations were identified—two nonsense mutations, E20X
and E118X; a 1-bp deletion, 27delG, leading to early
termination of protein; a missense mutation, S67P; and
a splice mutation, IVS25GrA, in the consensus se-
quence of the 5′ donor site of intron 2. The homozygous
status of the mutation in probands 7 and 8 was con-
firmed by sequencing of genomic DNA of both parents.
In two independent experiments, the electrophoretic
profile of reverse-transcriptase PCR (RT-PCR) products
from RNA isolated from proband 8 showed multiple
bands (fig. 1). RT-PCR products therefore were sub-
cloned, and 32 subclones were analyzed by sequencing.
This analysis revealed 30 abnormally spliced cDNAs and
2 normally spliced cDNAs. Among the 30mutant cDNAs,
only three classes were observed—cDNA with a deletion
of the last 76 bp of exon 2 (in 15/30), cDNA with a total
deletion of exon 2 (in 6/30), and cDNA with a 10-bp
insertion between exons 2 and 3 (in 9/30). The 10-bp
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Figure 1 Multiple abnormal HE1/NPC2 mRNAs in patient 8—PAGE analysis of RT-PCR products and schematic representations
of samples of HE1/NPC2 cDNA isolated from the patient’s fibroblasts.
insertion (gtgcataaaa) corresponds to the 5′ end of intron
2 (fig. 1).
Western Blot Studies of HE1/NPC2 in Patients with
NPC2
HE1/NPC2 was studied in cultured fibroblasts from
a normal subject and from patients with the S67P,
IVS25GrA, and E20X mutations. As shown in figure
2, no detectable protein was observed in fibroblasts with
either IVS2GrA or E20X, whereas S67P protein ap-
peared as a weak single band—instead of as a doublet,
as observed in normal fibroblasts.
The E20X Nonsense Mutation—a Frequent Mutant
Allele in Patients with NPC2
The most striking finding was that E20X was a highly
recurrent mutation, observed in five of the eight patients
included in the study. Interestingly, the ethnic origin of
the patients was quite varied (i.e., Italian, French, Al-
gerian, and Czech). Because the E20X mutation creates
a StuI restriction site, a simple screening test was devised.
Whereas the normal allele remains uncut (325 bp), the
mutant allele generates two shorter bands (177 bp and
148 bp) (fig. 3). Parents of probands 1, 3, and 6 were
studied by this test, confirming the homozygous status
of the mutation in these patients. The study of skin fi-
broblasts from the abortus also provided ultimate con-
firmation of four prenatally diagnosed affected siblings
in two families. In the eight families studied, the allele
frequency of E20X amounted to 56%.
Prenatal Diagnosis by Uncultured Chorionic-Villus
Sampling in a Family with E20X
In family 1, which had a homozygous E20Xmutation,
the third pregnancy was monitored by study of genomic
DNA extracted from uncultured chorionic-villus sam-
pling by the StuI restriction-enzyme test described above.
The fetus was found to be affected, and the pregnancy
was terminated at 11 wk gestation. The diagnosis was
later confirmed on cultured chorionic-villus samples, by
the conventional biochemical strategy (Vanier et al.
1992).
Genotype/Phenotype Correlations
Six of the eight patients withNPC2whowere included
in the study had a short life span; four (cases 1–4) did
not survive longer than ∼6 mo, owing to respiratory or
hepatic failure, and the remaining two (cases 5 and 6)
developed a neurological disease and died at age 19 mo
and 4 years, respectively. In all six of these patients, the
HE1/NPC2 mutation was obviously very deleterious,
leading to early termination of the HE1/NPC2 protein
(cases 1–3 and 6, E20X or frameshift; case 4, E118X).
All four unrelated patients homozygous for the recur-
rent E20X mutation presented with hepatosplenomeg-
aly and lung involvement, and three of the four presented
with a neonatal cholestatic icterus. Two patients died,
of respiratory failure, at age !6 mo, whereas two lived
longer and developed a severe neurological disease with
onset during infancy. Somewhat unexpectedly, the two
affected sibs with a homozygous S67P missense muta-
tion also showed a severe clinical course. Both had
marked splenomegaly and less-severe hepatomegaly. The
first-born child died early, of respiratory failure, and the
other child (case 7), also showing severe respiratory
problems, already had obvious neurological involvement
by age 18 mo.
Conversely, the two affected sisters in family 8 suffered
a quite different disease course, with onset of neurolog-
ical symptoms during late childhood, slow progression
of the disease with long survival, and no prominent pul-
monary involvement. The splice mutation underlying the
disease in this family was found to produce multiple
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Figure 2 Western blot of HE1/NPC2 in cultured fibroblasts
from three patients with NPC2 and from one normal subject. The
patients with NPC2 were homozygous for the indicated mutations.
mRNAs, with very small amounts (2/32 clones) of nor-
mal message, which may explain the definitely milder
disease course in these patients.
Discussion
To date, HE1/NPC2 mutations have been studied in nine
unrelated families with NPC2. All mutant alleles have
been identified. In the original study establishing HE1 as
the gene underlying NPC2, three mutant alleles corre-
sponded to the E20X nonsense mutation, and one allele
corresponded to a 1-bp deletion leading to a frameshift
(Naureckiene et al. 2000). The present study, of seven
additional families, has led to the identification of only
four novel mutations—comprising one nonsense muta-
tion (E118X), one frameshift (27delG), one missense mu-
tation (S67P), and one splice mutation (IVS25GrA)
—as well as to the finding of 7/14 E20X alleles (table 3).
E20X, with an overall allele frequency of 56%, was thus
established as the common mutant allele in patients with
NPC2. The variable ethnic origin of the families suggests
that a founder effect is unlikely. Five of the six mutations
thus far described lead to either premature termination
of the protein or severe alterations of the transcripts, and
the single missense mutation shows a clearly diminished
amount of HE1/NPC2 (table 1 and fig. 2). The situation
observed with HE1/NPC2 thus is in strong contrast with
the mutational pattern described for NPC1—for which
a wide variety of mutations have been documented, a
majority of which are missense mutations (Carstea et al.
1997; Greer et al. 1999; Yamamoto et al. 2000; Millat
et al. 2001; Ribeiro et al. 2001; Sun et al. 2001). Of the
missense mutations, several have been shown to result in
an essentially normal amount of NPC1 (Yamamoto et al.
2000; Millat et al. 2001; Ribeiro et al. 2001).
From a clinical point of view, the classic signs and
symptoms of NPC were present in all cases. Yet, in the
population of patients studied, the distribution of the
various clinical subtypes was very different from that
observed in NPC1. In the latter, patients with a juvenile
onset of neurological symptoms constitute ∼50% of the
cases, patients with an onset of neurological symptoms
during infancy constitute ∼20%, and patients dying, of
liver or respiratory failure, during the 1st year of life,
constitute, at most, 10% (Vanier et al. 1991; Vanier
2000). A first remarkable feature of the patients with
NPC2 was pronounced lung involvement, which was
prominent in six of the seven families for which detailed
clinical data were available (Pin et al. 1990; Schofer et
al. 1998; Elleder et al. 2001; table 1) and which led to
early death in six patients. The possible elective lung
involvement in patients with NPC2 has been described
elsewhere (Vanier et al. 1996; Schofer et al. 1998). Nev-
ertheless, this feature is not specific to NPC2. Although
the complementation group of some published cases
with severe lung involvement has not been reported (Ko-
vesi et al. 1996), we have recently definitively shown
one patient who died, of acute respiratory failure, at
age 2.5 mo, to belong to the NPC1 complementation
group (G.M. and M.T.V., unpublished data). Interest-
ingly, similar to the situation for neonatal cholestatic
icterus and neurological disease in families with NPC1
(Vanier et al. 1991;Millat et al. 2001), the study of family
7 indicates that fatal respiratory failure and a neurolog-
ical course can be seen in the same sibship. A second
remarkable observation is that, in three of the four fam-
ilies in which patients lived long enough to have neu-
rological symptoms, the neurological disease showed on-
set during infancy and a rapid course of decline.
The E20X mutation represents a null allele, because
all but the signal sequence of HE1/NPC2 is deleted. This
logically results in a severe disease phenotype, with all
homozygous patients dying at age !4 years. As discussed
above, neonatal respiratory manifestations were fre-
quent and could lead to early death at age !6 mo and,
thus, before onset of neurological symptoms. Patients
who had less-acute or no neonatal systemic manifes-
tations showed an onset of neurological symptoms at
age 1–2 years and did not survive past early childhood,
as is the rule in the infantile-neurological-onset form
(Vanier and Suzuki 1996; Vanier 2000). The 27delG
and E118X mutations are also associated with severe
disease and thus are likely to represent null alleles. It is
difficult to predict a priori the impact of missense mu-
tations. On the basis both of the neurological symptoms
already observed, at age 18 mo, in case 7 and of the
early death of her brother, it appears that the S67P
mutation markedly affects the function of HE1/NPC2.
This missense mutation is a nonconservative (polar-to-
hydrophobic) substitution that generates a proline, an
imino acid known to be particularly important for pro-
tein folding. The low level of S67P protein detected by
western blot analysis suggests that, in addition to having
a possibly deleterious effect on function, this mutation
may also affect biosynthesis and/or stability. The
IVS25GrA mutation is associated with a milder clin-
ical course, since the two siblings homozygous for this
mutation both showed a juvenile onset of the neuro-
logical disease and a prolonged survival. A more de-
tailed study showed that this splice mutation generated
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Figure 3 Restriction analysis of E20X. E20X creates a StuI restriction site. For families 1, 3, and 6 (tables 1 and 3), besides the
proband (P) or affected fetuses (f), the study included the father (F) and the mother (M). Lane P5 corresponds to case 5. Probands with
other HE1/NPC2 mutations (cases 8 and 4 [lanes P8 and P4, respectively]) showed a normal pattern and served as controls.
multiple abnormal mRNAs (fig. 3), a situation that has
been described in other lysosomal diseases (Ohno and
Suzuki 1988). In fibroblasts, a very small proportion
(2/32) of correctly spliced transcripts also was dem-
onstrated (fig. 3). Although this was not sufficient to
produce enough HE1/NPC2 for detection by our west-
ern blot assay (fig. 2), the presence of low levels of
functional protein presumably accounts for the milder
clinical course. The question of whether different tissues
could show a variability in the level of abnormally/nor-
mally spliced RNA transcribed from the IVS25GrA
mutation also can be raised. Such a situation has been
shown to occur in patients with cystic fibrosis who carry
the 3,84910-kb CrT mutation (Rave-Harel et al.
1997; Chiba-Falek et al. 1998) and has been considered
as the basis of disease variability.
One potential explanation for the overall very severe
clinical and mutational profile of the currently known
familieswithNPC2 is that genetic complementation stud-
ies might have been preferentially performed in patients
with a clinical presentation similar to that of the original
case (Steinberg et al. 1994). Although this, in some re-
spects, is true of earlier studies (Vanier et al. 1996), in
recent years genetic complementation tests have been per-
formed in a quite systematic way, in the laboratories of
two of the authors (A.H.F. and M.T.V.) of the present
article. Remarkably, the last three identified families with
NPC2 (families 1, 6, and 7) still showed the most com-
mon phenotype. Severe alterations of cholesterol traf-
ficking were present in six of the eight families reported
in the present study, including the family with a missense
mutation. A lesser degree of lysosomal cholesterol storage
and impairment of LDL-induced cholesterol esterification
was present in cells from patient 4 (Schofer et al. 1998)
and in cells from the two siblings in family 8. Yet, no
patient with the very mild impairment of cholesterol traf-
ficking that we have described as the “variant” biochem-
ical phenotype (Vanier et al. 1991) has been shown to
belong to the NPC2 complementation group. In fibro-
blasts from these patients, alterations are demonstrated
only after loading with pure LDL (Vanier et al. 1991;
Sun et al. 2001). We agree with Sun et al. (2001) that
genetic complementation tests using filipin staining are
difficult and not always reliable in patients with the var-
iant phenotype. In consideration of the fact that noNPC1
mutations could be demonstrated in several of their var-
iant NPC cell lines, Sun et al. (2001) suggested that such
patients were good candidates for a systematic screening
for HE1/NPC2 mutations. In our view, excluding the
presence of the most frequent NPC1 mutant alleles—
I1061T, P1007A, and G992W/ G992R—prior to HE1/
NPC2 sequencing is the proper strategy in newly diag-
nosed patients with variant NPC. In our survey of 53
variant cell lines, at least one allele carrying any of these
four mutations was found in 31 cases. To date, complete
sequencing of HE1/NPC2 cDNA from 10/22 remaining
cell lines was achieved, and no abnormality was detected
(G.M. and M.T.V., unpublished data). With regard to
systematic genetic testing of patients with “classic” NPC
(i.e., with severe cholesterol-trafficking alterations),
whether to test both for I1061T, on NPC1, as we had
proposed elsewhere (Millat et al. 1999), and for E20X,
onHE1/NPC2, should be considered before genetic com-
plementation analysis is performed.
Proper identification of patients with NPC2 and their
molecular characterization are important for two rea-
sons. First, it has an essential, practical impact on ge-
netic counseling; we have shown that the mutational
approach greatly improves prenatal testing, resulting in
significantly earlier diagnosis. Second, identification of
more HE1/NPC2 mutations may provide important
new information about functional domains of HE1/
NPC2 and advance the understanding of its exact func-
tion and of its potential interactions with NPC1.
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